{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:38:47Z","timestamp":1792373927013,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004543","name":"Chinese Scholarship Council","doi-asserted-by":"crossref","award":["202306100051"],"award-info":[{"award-number":["202306100051"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40262-025-01610-4","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:38:38Z","timestamp":1768214318000},"page":"621-632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness"],"prefix":"10.1007","volume":"65","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Bukkems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. G. C.","family":"van Hasselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. L. W.","family":"Koolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J. M. A.","family":"Hendrikx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Van der Hulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Zwaveling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn S. M. E.","family":"Theelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs H.","family":"Oude Munnink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3219-253X","authenticated-orcid":false,"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"issue":"25","key":"1610_CR1","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","volume":"34","author":"S Gettinger","year":"2016","unstructured":"Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2980\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1610_CR2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpt.3148","volume":"115","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Sanghavi K, Roy A, Murthy B, Bello A, Aras U, et al. Model-based dose selection of subcutaneous nivolumab in patients with advanced solid tumors. Clin Pharmacol Ther. 2024;115(3):488\u201397.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1610_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1093\/annonc\/mdz037","volume":"30","author":"Y Bi","year":"2019","unstructured":"Bi Y, Liu J, Furmanski B, Zhao H, Yu J, Osgood C, et al. Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective. Ann Oncol. 2019;30(4):644\u201351.","journal-title":"Ann Oncol"},{"key":"1610_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102974","volume":"139","author":"S George","year":"2025","unstructured":"George S, Bourlon MT, Overman MJ, Dixon M, Shelley K, Markus KJ, et al. Systematic literature review of intravenous versus subcutaneous administration of oncology therapies: a clinical, economic and patient perspective. Cancer Treat Rev. 2025;139:102974.","journal-title":"Cancer Treat Rev"},{"key":"1610_CR5","unstructured":"US Food and Drug Administration. FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection. 2024. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-and-hyaluronidase-nvhy-subcutaneous-injection. Accessed 26 Dec 2025."},{"key":"1610_CR6","unstructured":"US Food and Drug Administration. Pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pharmacokinetic-based-criteria-supporting-alternative-dosing-regimens-programmed-cell-death-receptor. https:\/\/www.fda.gov\/media\/151745\/download."},{"issue":"5","key":"1610_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s11523-024-01075-8","volume":"19","author":"D Moes","year":"2024","unstructured":"Moes D, Hendrikx J, Guchelaar HJ, Mathijssen RHJ, Bakker JL, Dezentj\u00e9 VO, et al. Model-informed development of a cost-saving dosing regimen for sacituzumab govitecan. Target Oncol. 2024;19(5):789\u201396.","journal-title":"Target Oncol"},{"issue":"1","key":"1610_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00280-025-04764-x","volume":"95","author":"CJ Op \u2019t Hoog","year":"2025","unstructured":"Op \u2019t Hoog CJ, Rieborn A, Moes DJA, Hendrikx JJ, van der Heijden MS, Franken MD, et al. Model-informed development of a cost-saving dosing regimen for enfortumab vedotin. Cancer Chemother Pharmacol. 2025;95(1):36.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1610_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s11523-023-00958-6","volume":"18","author":"R Ter Heine","year":"2023","unstructured":"Ter Heine R, van den Heuvel MM, Piet B, Deenen MJ, van der Wekken AJ, Hendriks LEL, et al. A systematic evaluation of cost-saving dosing regimens for therapeutic antibodies and antibody-drug conjugates for the treatment of lung cancer. Target Oncol. 2023;18(3):441\u201350.","journal-title":"Target Oncol"},{"issue":"4","key":"1610_CR10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/jcph.1984","volume":"62","author":"CJ Peer","year":"2022","unstructured":"Peer CJ, Heiss BL, Goldstein DA, Goodell JC, Figg WD, Ratain MJ. Pharmacokinetic simulation analysis of less frequent nivolumab and pembrolizumab dosing: pharmacoeconomic rationale for dose deescalation. J Clin Pharmacol. 2022;62(4):532\u201340.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1610_CR11","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cpt.875","volume":"103","author":"K Ogungbenro","year":"2018","unstructured":"Ogungbenro K, Patel A, Duncombe R, Nuttall R, Clark J, Lorigan P. Dose rationalization of pembrolizumab and nivolumab using pharmacokinetic modeling and simulation and cost analysis. Clin Pharmacol Ther. 2018;103(4):582\u201390.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"1610_CR12","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","volume":"36","author":"E Felip","year":"2025","unstructured":"Felip E, Rojas CI, Schenker M, Kowalski DM, Casarini IA, Cs\u00f6szi T, et al. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Ann Oncol. 2025;36(7):775\u201385.","journal-title":"Ann Oncol"},{"key":"1610_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0177-2","volume":"4","author":"S Agrawal","year":"2016","unstructured":"Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. 2016;4:72.","journal-title":"J Immunother Cancer"},{"key":"1610_CR14","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1200\/JCO.18.00045","volume":"36","author":"MJ Ratain","year":"2020","unstructured":"Ratain MJ, Goldstein DA. Time is money: optimizing the scheduling of nivolumab. J Clin Oncol. 2018;36:3074\u20136.","journal-title":"J Clin Oncol"},{"key":"1610_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2020.100604","volume":"93","author":"MA Printz","year":"2020","unstructured":"Printz MA, Dychter SS, DeNoia EP, Harrigan R, Sugarman BJ, Zepeda M, et al. A phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human hyaluronidase PH20 administered intravenously in healthy volunteers. Curr Ther Res Clin Exp. 2020;93:100604.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"6","key":"1610_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.tox.2013.07.009","volume":"315","author":"K McNally","year":"2014","unstructured":"McNally K, Cotton R, Hogg A, Loizou G. PopGen: a virtual human population generator. Toxicology. 2014;315(6):70\u201385.","journal-title":"Toxicology"},{"issue":"21","key":"1610_CR17","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Caro RB, Zurawski B, Kim S-W, Costa EC, et al. Nivolumab plus Ipilimumab in advanced non\u2013small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"key":"1610_CR18","unstructured":"medicijnkosten.nl. OPDIVO INFVLST CONC 10MG\/ML BOTTLE 4ML. 2025. Available from: https:\/\/www.medicijnkosten.nl\/medicijn?artikel=OPDIVO+INFVLST+CONC+10MG%2FML+FLACON++4ML&id=a4090638cee0261941b8991f3132ad5f. Accessed 26 Dec 2025."},{"key":"1610_CR19","unstructured":"US Food and Drug Administration. Clinical pharmacology and biopharmaceutic review (nivolumab). Application number: 125554Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125554orig1s000clinpharmr.pdf."},{"issue":"12","key":"1610_CR20","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","volume":"23","author":"R Malmberg","year":"2022","unstructured":"Malmberg R, Zietse M, Dumoulin DW, Hendrikx J, Aerts J, van der Veldt AAM, et al. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. Lancet Oncol. 2022;23(12):e552\u201361.","journal-title":"Lancet Oncol"},{"issue":"26","key":"1610_CR21","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"10","key":"1610_CR22","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","volume":"5","author":"SL Topalian","year":"2019","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411\u201320.","journal-title":"JAMA Oncol"},{"issue":"13","key":"1610_CR23","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430\u20137.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1610_CR24","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122\u201333.","journal-title":"N Engl J Med"},{"issue":"11","key":"1610_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.18.01998","volume":"37","author":"C Lebb\u00e9","year":"2019","unstructured":"Lebb\u00e9 C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 Trial. J Clin Oncol. 2019;37(11):867\u201375.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1610_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","volume":"18","author":"MD Hellmann","year":"2017","unstructured":"Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31\u201341.","journal-title":"Lancet Oncol"},{"issue":"34","key":"1610_CR27","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","volume":"35","author":"HJ Hammers","year":"2017","unstructured":"Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 Study. J Clin Oncol. 2017;35(34):3851\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1610_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/psp4.12143","volume":"6","author":"G Bajaj","year":"2017","unstructured":"Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):58\u201366.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"1610_CR29","doi-asserted-by":"publisher","first-page":"11472","DOI":"10.1038\/s41598-019-47910-1","volume":"9","author":"LA De Sousa","year":"2019","unstructured":"De Sousa LA, Battin C, Jutz S, Leitner J, Hafner C, Tobias J, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling. Sci Rep. 2019;9(1):11472.","journal-title":"Sci Rep"},{"issue":"5","key":"1610_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114754","volume":"157","author":"JDJ Verdonk","year":"2025","unstructured":"Verdonk JDJ, Piet B, Ter Heine R, van den Heuvel MM, Smeets RL, Koenen H. Ex vivo pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals a critical gap between receptor occupancy and T cell functionality. Int Immunopharmacol. 2025;157(5):114754.","journal-title":"Int Immunopharmacol"},{"key":"1610_CR31","unstructured":"ClinicalTrials.gov. Comparing dosing intervals of nivolumab or pembrolizumab in locally advanced or metastatic cancers. 2020. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04295863. Accessed 26 Dec 2025."},{"key":"1610_CR32","unstructured":"ClinicalTrials.gov. Clinical trials for 2021-001707-32. 2021. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2021-001707-32. Accessed 26 Dec 2025."},{"issue":"12","key":"1610_CR33","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/jcph.6108","volume":"64","author":"J Wen","year":"2024","unstructured":"Wen J, McCann S, Balevic SJ, Muller WJ, Hornik CD, Autmizguine J, et al. Pharmacokinetics of dexamethasone in children and adolescents with obesity. J Clin Pharmacol. 2024;64(12):1491\u2013504.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"1610_CR34","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00228-024-03698-2","volume":"80","author":"R Liao","year":"2024","unstructured":"Liao R, Chen L, Cheng X, Li H, Wang T, Dong Y, et al. Estimation of linezolid exposure in patients with hepatic impairment using machine learning based on a population pharmacokinetic model. Eur J Clin Pharmacol. 2024;80(8):1241\u201351.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1610_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/0896860820950924","volume":"41","author":"K Hennessy","year":"2021","unstructured":"Hennessy K, Capparelli EV, Romanowski G, Alejandro L, Murray W, Benador N. Intraperitoneal vancomycin for peritoneal dialysis-associated peritonitis in children: evaluation of loading dose guidelines. Perit Dial Int. 2021;41(2):202\u20138.","journal-title":"Perit Dial Int"}],"updated-by":[{"DOI":"10.1007\/s40262-026-01627-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000}},{"DOI":"10.1007\/s40262-026-01649-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000}}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01610-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01610-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01610-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:41:51Z","timestamp":1779255711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01610-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1610"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01610-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: to correct Table 1 and a sentence.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40262-026-01627-3","URL":"https:\/\/doi.org\/10.1007\/s40262-026-01627-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":12,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":13,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":14,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40262-026-01649-x","URL":"https:\/\/doi.org\/10.1007\/s40262-026-01649-x","order":15,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dirk Jan A.R. Moes is an Editorial Board member of\n                      Clinical Pharmacokinetics\n                      . He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.\u00a0All other authors declare no conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All the model codes are provided in the supplementary materials.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"YW, LHB, EFS, RH, HJG, and DJARM contributed to the research design, YW, LHB, and DJARM performed the research, analyzed the data, and wrote the manuscript, and RH, JGCH, SLWK, JJMA, TH, EK, JZ, AB, MMH, WT, THOM, EFS, and HJG reviewed and revised the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}